Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 1
2019 5
2020 4
2021 2
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer.
Chakraborty G, Nandakumar S, Hirani R, Nguyen B, Stopsack KH, Kreitzer C, Rajanala SH, Ghale R, Mazzu YZ, Pillarsetty NVK, Lee GM, Scher HI, Morris MJ, Traina T, Razavi P, Abida W, Durack JC, Solomon SB, Vander Heiden MG, Mucci LA, Wibmer AG, Schultz N, Kantoff PW. Chakraborty G, et al. Among authors: mazzu yz. Clin Cancer Res. 2022 Aug 15;28(16):3603-3617. doi: 10.1158/1078-0432.CCR-21-4272. Clin Cancer Res. 2022. PMID: 35670774 Free PMC article.
Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.
Yoshikawa Y, Stopsack KH, Wang XV, Chen YH, Mazzu YZ, Burton F, Chakraborty G, Rajanala SH, Hirani R, Nandakumar S, Lee GM, Frank D, Davicioni E, Liu G, Carducci MA, Azuma H, Kantoff PW, Sweeney CJ. Yoshikawa Y, et al. Among authors: mazzu yz. Mol Oncol. 2022 Dec;16(22):3994-4010. doi: 10.1002/1878-0261.13314. Epub 2022 Oct 2. Mol Oncol. 2022. PMID: 36087093 Free PMC article.
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.
Chakraborty G, Armenia J, Mazzu YZ, Nandakumar S, Stopsack KH, Atiq MO, Komura K, Jehane L, Hirani R, Chadalavada K, Yoshikawa Y, Khan NA, Chen Y, Abida W, Mucci LA, Lee GM, Nanjangud GJ, Kantoff PW. Chakraborty G, et al. Among authors: mazzu yz. Clin Cancer Res. 2020 Apr 15;26(8):2047-2064. doi: 10.1158/1078-0432.CCR-19-1570. Epub 2019 Dec 3. Clin Cancer Res. 2020. PMID: 31796516 Free PMC article.
Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors.
Chakraborty G, Patail NK, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq M, Jehane LE, Stopsack KH, Lee GM, Abida W, Morris MJ, Mucci LA, Danila D, Kantoff PW. Chakraborty G, et al. Among authors: mazzu yz. Clin Cancer Res. 2021 Mar 15;27(6):1792-1806. doi: 10.1158/1078-0432.CCR-20-2483. Epub 2020 Dec 17. Clin Cancer Res. 2021. PMID: 33334906 Free PMC article.
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW. Komura K, et al. Among authors: mazzu yz. J Clin Invest. 2018 Jul 2;128(7):2979-2995. doi: 10.1172/JCI96769. Epub 2018 Jun 4. J Clin Invest. 2018. PMID: 29863497 Free PMC article.
15 results